FDMT - 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC | Benzinga
- 4D-710 interim data to be presented in plenary and symposium sessions at the North American Cystic Fibrosis Conference in Phoenix, Arizona held on November 2-4, 2023
- Company to host webcast on Wednesday, November 1, 2023 at 4:30 p.m. ET
EMERYVILLE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a clinical-stage genetic medicines company with three novel, highly targeted next generation AAV vectors currently in the clinic, today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET.
The interim data will include additional safety and clinical activity follow-up on Cohort 1 (n=3) at the 1E15 vg dose level and initial safety and biomarker data from Cohort 2 (n=3-6) at the 2E15 vg dose level. The Company previously announced positive interim data from Cohort 1 at the European Cystic Fibrosis Society 46th Annual Meeting.
2023 NACFC Presentation Details:
| Plenary Session: |
| Genetic Therapies for All: Harnessing Cross-Disease Knowledge for Breakthroughs in Cystic Fibrosis |
| Date/Time: |
| Thursday, November 2, 2023 at 4:30 p.m. MST |
| Presenter: |
| Paul McCray, Jr., MD, University of Iowa |
| Symposium Session: |
| Building the Path to the Cure: the role of AAV therapy |
| Date/Time: |
| Friday, November 3, 2023 at 3:30 ... |